Not available
Quote | KalVista Pharmaceuticals Inc. (NASDAQ:KALV)
Last: | $11.79 |
---|---|
Change Percent: | 1.45% |
Open: | $11.55 |
Close: | $11.79 |
High: | $12.07 |
Low: | $11.45 |
Volume: | 267,568 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | KalVista Pharmaceuticals Inc. (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
2024-06-24 02:53:53 ET Summary KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in June 2024. The company targets 2025 US, EU, UK, and J...
Message Board Posts | KalVista Pharmaceuticals Inc. (NASDAQ:KALV)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $KALV hod6.24 | znewcar1 | investorshangout | 12/28/2022 7:21:21 PM |
I would not even buy the shares at $20. | Femto99 | investorshub | 02/11/2021 5:16:09 PM |
All in puts! | Femto99 | investorshub | 02/11/2021 4:02:31 PM |
znewcar1: KALV 114% v34,8M c33.50 f17,9M preMH51.3 HOD44.7 S28.9 | znewcar1 | investorshangout | 02/09/2021 9:17:38 PM |
Boom! Killed it with puts today! | Stock_Barber | investorshub | 02/09/2021 9:01:35 PM |
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...
– US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours – – Despite growing use of long-term prophylaxis therapies in the US on-demand treatment prescription volumes stay stable...